Efficacy and safety of apatinib plus chemotherapy vs. chemotherapy alone for the treatment of advanced‑stage non‑small cell lung cancer: A meta‑analysis

Qin,Shuai; Han,Xiao; Li,Zhuying

doi:10.3892/ol.2023.14158

Efficacy and safety of apatinib plus chemotherapy vs. chemotherapy alone for the treatment of advanced‑stage non‑small cell lung cancer: A meta‑analysis

Authors:
- Shuai Qin
- Xiao Han
- Zhuying Li
View Affiliations

Affiliations: Department of Integrated Traditional Chinese and Western Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, P.R. China, Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, P.R. China
Published online on: November 17, 2023 https://doi.org/10.3892/ol.2023.14158
Article Number: 25
Copyright: © Qin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Apatinib has been widely applied for the treatment of gastrointestinal cancer since its development; however, available conclusive data regarding its use in non‑small cell lung cancer (NSCLC) are lacking. Thus, the present meta‑analysis aimed to compare the efficacy and safety of the use of apatinib plus chemotherapy vs. chemotherapy alone for the treatment of patients with advanced‑stage NSCLC. Published studies reporting the treatment response, progression‑free survival (PFS), overall survival (OS) and adverse events in patients with advanced‑stage NSCLC treated with apatinib plus chemotherapy or chemotherapy alone were searched using the PubMed, China National Knowledge Infrastructure, EMBASE, Chongqing VIP Information, Cochrane and Wanfang databases until February 2023. Finally, 18 studies involving 677 patients with NSCLC receiving apatinib plus chemotherapy and 672 patients with NSCLC receiving chemotherapy were included in the present analysis. Apatinib plus chemotherapy was found to increase the objective response rate [relative risk (RR), 1.60; 95% confidence interval (CI), 1.38‑1.86] and disease control rate (RR, 1.29; 95% CI, 1.21‑1.38) compared to chemotherapy alone. Of note, apatinib plus chemotherapy also prolonged PFS compared with chemotherapy alone (hazard ratio, 0.54; 95% CI, 0.35‑0.73), while no OS data were retrievable from the included studies. With regard to safety, apatinib plus chemotherapy elevated the risk of developing hypertension (RR, 3.78; 95% CI, 1.81‑7.93) and hand‑foot syndrome (RR, 6.51; 95% CI, 3.70‑11.46) vs. chemotherapy alone; however, no difference was observed between the two regimens in terms of the incidence of other adverse events. Furthermore, the bias was low and the pooled findings were reliable/stable, as indicated by a sensitivity analysis. On the whole, the present study demonstrates that apatinib plus chemotherapy increases the treatment response and PFS vs. chemotherapy alone, while it also elevates the risk of developing hypertension and hand‑foot syndrome in patients with advanced‑stage NSCLC.

View Figures

View References

1	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, et al: Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 20:497–530. 2022. View Article : Google Scholar : PubMed/NCBI
2	Chen P, Liu Y, Wen Y and Zhou C: Non-small cell lung cancer in China. Cancer Commun (Lond). 42:937–970. 2022. View Article : Google Scholar : PubMed/NCBI
3	Wei W, Zeng H, Zheng R, Zhang S, An L, Chen R, Wang S, Sun K, Matsuda T, Bray F and He J: Cancer registration in China and its role in cancer prevention and control. Lancet Oncol. 21:e342–e349. 2020. View Article : Google Scholar : PubMed/NCBI
4	Alexander M, Kim SY and Cheng H: Update 2020: Management of non-small cell lung cancer. Lung. 198:897–907. 2020. View Article : Google Scholar : PubMed/NCBI
5	Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K and Lou Y: Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 13:582020. View Article : Google Scholar : PubMed/NCBI
6	Melosky B, Wheatley-Price P, Juergens RA, Sacher A, Leighl NB, Tsao MS, Cheema P, Snow S, Liu G, Card PB and Chu Q: The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. Lung Cancer. 160:136–151. 2021. View Article : Google Scholar : PubMed/NCBI
7	Wang X, Zhong D, Zhang J, Du N, Ren Y, Gao J, Liu L, Yu J, Li X, Ma L, et al: Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: A sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202). J Gastrointest Oncol. 13:1679–1689. 2022. View Article : Google Scholar : PubMed/NCBI
8	Tang Z, Wang Y, Yu Y, Cui Y, Liang L, Xu C, Shen Z, Shen K, Wang X, Liu T and Sun Y: Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: A single-arm, open-label, phase 2 trial. BMC Med. 20:1072022. View Article : Google Scholar : PubMed/NCBI
9	Fathi Maroufi N, Rashidi MR, Vahedian V, Akbarzadeh M, Fattahi A and Nouri M: Therapeutic potentials of apatinib in cancer treatment: Possible mechanisms and clinical relevance. Life Sci. 241:1171062020. View Article : Google Scholar : PubMed/NCBI
10	Zhao J, Yu H, Han T, Wang W, Tong W and Zhu X: A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer. J BUON. 24:2267–2272. 2019.PubMed/NCBI
11	Hu R, Li T, Hui K, Chen Z, Wang N, Wu X, Ge L and Zhou L: Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC. Mol Med Rep. 22:3935–3943. 2020.PubMed/NCBI
12	Xu J, Liu X, Yang S, Zhang X and Shi Y: Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. Asia Pac J Clin Oncol. 14:264–269. 2018. View Article : Google Scholar : PubMed/NCBI
13	Guo Y and Jing X: Efficacy and safety of docetaxel plus apatinib as a second-line treatment for advanced nonsquamous non-small cell lung cancer. Chin J Clin Oncol. 44:544–546. 2017.
14	Chen E, Chen Z, Chen M and Che M: Clinical effect evaluation of apatinib mesylate tablets in the treatment of advanced non-small cell lung cancer. China Mod Med. 24:91–93. 2017.
15	Liu X and Zheng J: Curative effect of second-line chemotherapy of apatinib combined with docetaxel on advanced non-squamous non-small-cell lung cancer. Pract J Card Cereb Pneumal Vasc Dis. 26:104–107. 2018.
16	Shang K, Hu R and Hu J: Effects of apatinib combined with docetaxel on CEA, SCC and CA125 in second-line treatment of patients with advanced non-small cell lung cancer. Pract J Cancer. 34:1172–1175. 2019.
17	Luo R and Li B: Clinical effect of apatinib combined with chemotherapy on patients with advanced non-small cell lung cancer after failure of first-line treatment. Oncol Prog. 17:1809–1812. 2019.
18	Yu Z, Cai X, Xu Z, He Z, Lai J, Wang W, Zhang J, Kong W, Huang X, Chen Y, et al: Apatinib plus chemotherapy as a second-line treatment in unresectable non-small cell lung carcinoma: A randomized, controlled, multicenter clinical trial. Oncologist. 25:e1640–e1649. 2020. View Article : Google Scholar : PubMed/NCBI
19	Guo C, Dong J, Yin Y, Cui J, Gao Y and Zhang J: The efficacy and safety of apatinib combined with chemotherapy in the first-line treatment of driver-negative advanced non-small cell lung cancer. Syst Med. 5:10–12. 2020.
20	Xie MQ, Wen B, Xu HX and Song YR: Efficacy of apatinib combined with cisplatin and paclitaxel in the treatment of driver gene wild-type advanced non-squamous non-small cell lung cancer. J Basic Clin Oncol. 33:198–200. 2020.
21	Li S: Effect of Apatinib mesylate tablets combined with paclitaxel injection on the efficacy of patients with non-small cell lung cancer. Contemp Med. 26:175–177. 2020.
22	Cui YJ, Liu J, Liu MM and Zhang HZ: Observation on the clinical effect of apatinib combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Pak J Med Sci. 37:1036–1041. 2021. View Article : Google Scholar : PubMed/NCBI
23	Chen P, Chen W and Zhang J: Efficacy, safety and prognosis of apatinib plus docetaxel compared with docetaxel in the second line treatment in advanced non-squamous non-small cell lung cancer. J Mod Oncol. 29:1513–1519. 2021.
24	Huang Y, Lin Q, You X, Cao X and Li W: Clinical effects of apatinib in combination with cisplatin and paclitaxel chemotherapy for advanced non-small cell lung cancer. J Math Med. 34:1669–1671. 2021.
25	Liu J, Pan X and Zheng G: Efficacy of apatinib mesylate in combination with paclitaxel in advanced non-small cell lung cancer and the effect on serum tumor markers. Shanxi Med J. 50:784–786. 2021.
26	Guo H: Clinical effect of apatinib mesylate tablets combined with chemotherapy for advanced non-small cell lung cancer. Med Forum. 25:3204–3206. 2021.
27	Song Y, Zhao Q and Lv J: Effect of apatinib combined with chemotherapy on multiple tumor markers in patients with advanced non-small cell lung cancer and its short-term efficacy. Int J Pathol Clin Med. 41:2824–2829. 2021.
28	Chen L, Zhou L, Jin X, Ma S and Jiang X: Efficacy analysis of apatinib combined with paclitaxel and cisplatin in the treatment of non-small cell lung cancer. World J Complex Med. 8:187–190. 1982022.
29	Lu M: Effects of apatinib combined with paclitaxel in treatment of elderly patients with advanced non-small cell lung cancer. Med J Chin People's Health. 34:28–31. 2022.
30	Li Z, Liu Z, Wu Y, Li H, Sun Z, Han C, Zhang X and Zhang J: Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis. Thorac Cancer. 12:2838–2848. 2021. View Article : Google Scholar : PubMed/NCBI
31	Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al: The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 343:d59282011. View Article : Google Scholar : PubMed/NCBI
32	Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.
33	Pang LL, Gan JD, Huang YH, Liao J, Zhuang WT, Ali WA, Hong SD, Zhang L and Fang WF: Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. BMC Cancer. 23:722023. View Article : Google Scholar : PubMed/NCBI
34	Manzo A, Montanino A, Carillio G, Costanzo R, Sandomenico C, Normanno N, Piccirillo MC, Daniele G, Perrone F, Rocco G and Morabito A: Angiogenesis inhibitors in NSCLC. Int J Mol Sci. 18:20212017. View Article : Google Scholar : PubMed/NCBI
35	Zhang H: Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 9:6075–6081. 2015. View Article : Google Scholar : PubMed/NCBI
36	Feng J and Qin S: The synergistic effects of Apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model. Onco Targets Ther. 11:3047–3057. 2018. View Article : Google Scholar : PubMed/NCBI
37	Wei B, Wang Y, Wang J, Cai X, Xu L, Wu J, Wang Y, Liu W, Gu Y, Guo W and Xu Q: Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway. Cancer Cell Int. 20:1982020. View Article : Google Scholar : PubMed/NCBI
38	Shi J, Yang H, Lv T, Pan H and Yang B: Efficacy of platinum drugs in the treatment of elderly patients with advanced non-small cell lung cancer and their effects on prognosis and survival. J BUON. 25:1737–1744. 2020.PubMed/NCBI
39	Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C and Westeel V: Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database Syst Rev. 4:CD0132572021.PubMed/NCBI
40	Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 34:1448–1454. 2016. View Article : Google Scholar : PubMed/NCBI
41	Geng R, Song L, Li J and Zhao L: The safety of apatinib for the treatment of gastric cancer. Expert Opin Drug Saf. 17:1145–1150. 2018. View Article : Google Scholar : PubMed/NCBI
42	Knezevic CE and Clarke W: Cancer chemotherapy: The case for therapeutic drug monitoring. Ther Drug Monit. 42:6–19. 2020. View Article : Google Scholar : PubMed/NCBI
43	Li C, Ma L, Wang Q, Shao X, Guo L, Chen J, Wang W and Yu J: Rho kinase inhibition ameliorates vascular remodeling and blood pressure elevations in a rat model of apatinib-induced hypertension. J Hypertens. 40:675–684. 2022. View Article : Google Scholar : PubMed/NCBI
44	Xia H, Zhou C, Luo Z, Zhang P, Zhu L and Gong Z: Apatinib-induced hand-foot skin reaction in chinese patients with liver cancer. Front Oncol. 11:6243692021. View Article : Google Scholar : PubMed/NCBI
45	Botrel TE, Clark O, Clark L, Paladini L, Faleiros E and Pegoretti B: Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis. Lung Cancer. 74:89–97. 2011. View Article : Google Scholar : PubMed/NCBI
46	Zhang S, Mao XD, Wang HT, Cai F and Xu J: Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: A systematic review and meta-analysis. BMJ Open. 6:e0117142016. View Article : Google Scholar : PubMed/NCBI